A 8-Week, Open-Label, Phase 1 Study To Evaluate Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2015
At a glance
- Drugs Atorvastatin (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 20 Mar 2012 This trial is not authorised in Netherlands.
- 20 Mar 2012 Planned number of patients changed from 36 to 39 as reported by European Clinical Trials Database.